#United States #Columbus #Rare Diseases #Specialty Pharmacy #Orsini

Orsini Launches Integrated Specialty Pharmacy and 3PL Solution

On October 20, 2025, Orsini, well-recognized as a leader in pharmacy solutions for rare diseases, proudly announced the opening of its integrated specialty pharmacy and third-party logistics (3PL) service at a new facility in Columbus, Ohio. This innovative launch marks not just an expansion of their operations, but a significant enhancement of their capabilities aimed specifically at supporting biopharmaceutical partners in the management of therapies for rare diseases.

Facility Highlights

The newly operational Columbus facility is fully licensed to dispense medications across all 50 states, ensuring nationwide availability of its services. This facility is equipped with a comprehensive infrastructure that features specialty pharmacy redundancy and co-located 3PL capabilities. Particularly noteworthy is the advanced ultra-cold storage technology unique to this facility, designed to support cutting-edge gene and cell therapy programs essential for the treatment of rare diseases.

By integrating specialty pharmacy and 3PL services in one location, Orsini has developed a model tailored to the complex needs of rare disease therapies. This synergy not only improves operational efficiency but also provides a seamless experience for both patients and biopharma partners collaborating with Orsini as their exclusive specialty pharmacy provider.

Commitment to Patients

Brandon Tom, the CEO of Orsini, articulated the company's vision, stating, "This launch represents more than an expansion — it's an investment in our mission to improve the lives of patients and families affected by rare diseases." With this new facility, Orsini is set to significantly enhance its capabilities in delivering intensive, personalized care to patients requiring treatments for complex and often under-recognized conditions.

The Columbus facility is also anticipated to be the first location supporting Orsini's partnership with Immedica Pharma, a biopharmaceutical entity specializing in products for rare diseases. Such collaborations are pivotal, as they underline Orsini's role in the critical junction between innovative therapy developers and the patients who need these life-changing treatments.

A Legacy of Care

Since its inception in 1987, Orsini has dedicated itself to providing patients not just with medications, but with comprehensive and compassionate care. The firm has gained recognition as a front-runner in the domain of rare diseases and gene therapies, working alongside healthcare providers, biopharma innovators, and payors to ensure patients gain access to revolutionary treatment options.

Their services include pharmacy distribution, patient engagement programs, clinical management, and even home infusion services, all designed to streamline the connection between patients and advanced therapies. The company's high-touch care model emphasizes the importance of personalized attention; every interaction with their trained therapy care teams is focused on ensuring that no patient is left behind.

Accredited by various organizations including the Accreditation Commission for Health Care (ACHC) and certified by URAC as a Rare Disease Pharmacy Center of Excellence, Orsini sets itself apart with a commitment to high-quality standards that prioritize patient welfare and therapeutic outcomes.

As the healthcare landscape continues to evolve, Orsini's pioneering efforts in establishing this new facility reflect a strategic approach to meeting the growing demand for specialized healthcare services tailored to rare diseases. Their commitment to integrating innovative pharmacy solutions with logistics exemplifies a forward-thinking model aimed at enhancing the overall patient experience and advancing care for those with rare and complex medical conditions.

For more details about Orsini's offerings and its latest initiatives, you can visit their website at www.orsini.com.